In English
Enciclopedia de Salud

Health Condition

High Blood Pressure (Hypertension)

About This Condition

Approximately 90% of people with high blood pressure have “essential” or “idiopathic” hypertension, for which the cause is poorly understood. The terms “hypertension” and “high blood pressure” as used here refer only to this most common form and not to pregnancy-induced hypertension or hypertension clearly linked to a known cause, such as Cushing’s syndrome, pheochromocytoma, or kidney disease. Hypertension must always be evaluated by a healthcare professional. Extremely high blood pressure (malignant hypertension) or rapidly worsening hypertension (accelerated hypertension) almost always requires treatment with conventional medicine. People with mild to moderate high blood pressure should work with a doctor before attempting to use the information contained here, as blood pressure requires monitoring and in some cases the use of blood pressure-lowering drugs.

As with conventional drugs, the use of natural substances sometimes controls blood pressure if taken consistently but does not lead to a cure for high blood pressure. Thus, someone whose blood pressure is successfully reduced by weight loss, avoidance of salt, and increased intake of fruits and vegetables would need to maintain these changes permanently in order to retain control of blood pressure. Left untreated, hypertension significantly increases the risk of stroke and heart disease.


Essential hypertension is usually without symptoms until complications develop. The symptoms of complications depend on the organs involved.

Other Therapies

Healthcare practitioners may also recommend lifestyle modifications, such as moderate weight reduction and a decrease in salt intake. Though essential hypertension has no cure, treatment can modify its course and reduce the risk of complications.


1. Naveed M,Hejazi V, Abbas M, et al. Chlorogenic acid (CGA): A pharmacological review and call for further research. Biomed Pharmacother 2018;97:67–74.

2. Pimpley V, Patil S,Srinivasan K, et al. The chemistry of chlorogenic acid from green coffee and its role in attenuation of obesity and diabetes. Prep Biochem Biotechnol 2020;50:969–78.

3. Han B, Nazary-Vannani A, Talaei S, et al. The effect of green coffee extract supplementation on blood pressure: A systematic review and meta-analysis of randomized controlled trials. Phytother Res 2019 Nov;33:2918–26.

4. Bercea CI, Cottrell GS, Tamagnini F, et al. Omega-3 polyunsaturated fatty acids and hypertension: a review of vasodilatory mechanisms of docosahexaenoic acid and eicosapentaenoic acid. Br J Pharmacol 2021;178:860–77.

5. Matsumoto C, Yoruk A, Wang L, et al. Fish and omega-3 fatty acid consumption and risk of hypertension. J Hypertens 2019 06;37(6):1223–9.

6. Yang B, Shi MQ, Li ZH, et al. Fish, Long-Chain n-3 PUFA and Incidence of Elevated Blood Pressure: A Meta-Analysis of Prospective Cohort Studies. Nutrients 2016 Jan;8(1):58.

7. Miller PE, Van Elswyk M, Alexander DD. Long-chain omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and blood pressure: a meta-analysis of randomized controlled trials. Am J Hypertens 2014 Jul;27(7):885–96.

8. Ried K. Garlic lowers blood pressure in hypertensive subjects, improves arterial stiffness and gut microbiota: A review and meta-analysis. Exp Ther Med 2020;19:1472–8.

9. Schwingshackl L, Missbach B, Hoffmann G. An umbrella review of garlic intake and risk of cardiovascular disease. Phytomedicine. 2016 Oct;23(11):1127–33.

10. Xiong XJ, Wang PQ, Li SJ, et al. Garlic for hypertension: A systematic review and meta-analysis of randomized controlled trials. Phytomedicine. 2015;22:352–61.

11. Ried K, Travica N, Sali A. The effect of aged garlic extract on blood pressure and other cardiovascular risk factors in uncontrolled hypertensives: the AGE at Heart trial. Integr Blood Press Control 2016;9:9–21.

12. Mahdavi-Roshan M, Nasrollahzadeh J, Mohammad Zadeh A, Zahedmehr A. Does Garlic Supplementation Control Blood Pressure in Patients with Severe Coronary Artery Disease? A Clinical Trial Study. Iran Red Crescent Med J 2016;18:e23871.

13. Zhu Y, Anand R, Geng X, et al. A mini review: garlic extract and vascular diseases. Neurol Res 2018;40:421–425.

14. Choudhary PR, Jani RD, Sharma MS. Effect of Raw Crushed Garlic (Allium sativum L.) on Components of Metabolic Syndrome. J Diet Suppl 2018;15:499–506.

15. Bahadoran Z, Mirmiran P, Momenan AA, et al. Allium vegetable intakes and the incidence of cardiovascular disease, hypertension, chronic kidney disease, and type 2 diabetes in adults: a longitudinal follow-up study. J Hypertens 2017;35:1909–16.

16. Odai T, Terauchi M, Kato K, et al. Effects of Grape Seed Proanthocyanidin Extract on Vascular Endothelial Function in Participants with Prehypertension: A Randomized, Double-Blind, Placebo-Controlled Study. Nutrients 2019;11:2844.

17. Park E, Edirisinghe I, Choy YY, et al. Effects of grape seed extract beverage on blood pressure and metabolic indices in individuals with pre-hypertension: a randomised, double-blinded, two-arm, parallel, placebo-controlled trial. Br J Nutr 2016;115:226–38.

18. Belcaro G, Ledda A, Hu S, et al. Grape seed procyanidins in pre- and mild hypertension: a registry study. Evid Based Complement Alternat Med 2013;2013:313142.

19. Zhang H, Liu S, Li L, et al. The impact of grape seed extract treatment on blood pressure changes: A meta-analysis of 16 randomized controlled trials. Medicine (Baltimore) 2016;95:e4247.

20. Jeffery TD, Richardson ML. A review of the effectiveness of hibiscus for treatment of metabolic syndrome. J Ethnopharmacol 2021;270:113762.

21. Amos A, Khiatah B. Mechanisms of Action of Nutritionally Rich Hibiscus sabdariffa's Therapeutic Uses in Major Common Chronic Diseases: A Literature Review. Journal of the J Am Coll Nutr 2021:1–8.

22. Jalalyazdi M, Ramezani J, Izadi-Moud A, et al. Effect of hibiscus sabdariffa on blood pressure in patients with stage 1 hypertension. J Adv Pharm Technol Res 2019;10:107–11.

23. Al-Anbaki M, Nogueira RC, Cavin AL, et al. Treating Uncontrolled Hypertension with Hibiscus sabdariffa When Standard Treatment Is Insufficient: Pilot Intervention. J Altern Complement Med 2019;25:1200–05.

24. Serban C, Sahebkar A, Ursoniu S, et al. Effect of sour tea (Hibiscus sabdariffa L.) on arterial hypertension: a systematic review and meta-analysis of randomized controlled trials. J Hypertens 2015;33:1119–27.

25. Seck SM, Doupa D, Dia DG, et al. Clinical efficacy of African traditional medicines in hypertension: A randomized controlled trial with Combretum micranthum and Hibiscus sabdariffa. J Hum Hypertens 2017;12;32:75–81.

26. Elkafrawy N, Younes K, Naguib A, et al. Antihypertensive efficacy and safety of a standardized herbal medicinal product of Hibiscus sabdariffa and Olea europaea extracts (NW Roselle): A phase-II, randomized, double-blind, captopril-controlled clinical trial. Phytother Res 2020;34:3379–87.

27. Bourqui A, Niang EAB, Graz B, et al. Hypertension treatment with Combretum micranthum or Hibiscus sabdariffa, as decoction or tablet: a randomized clinical trial. J Hum Hypertens 2020 Sep.

28. Nwachukwu DC, Aneke EI, Obika LF, et al. Effects of aqueous extract of Hibiscus sabdariffa on the renin-angiotensin-aldosterone system of Nigerians with mild to moderate essential hypertension: A comparative study with lisinopril. Indian J Pharmacol 2015;47:540–5.

29. Nwachukwu DC, Aneke E, Nwachukwu NZ, et al. Effect of Hibiscus sabdariffaon blood pressure and electrolyte profile of mild to moderate hypertensive Nigerians: A comparative study with hydrochlorothiazide. Niger J Clin Pract 2015;18:762–70.

30. Kostov K, Halacheva L. Role of Magnesium Deficiency in Promoting Atherosclerosis, Endothelial Dysfunction, and Arterial Stiffening as Risk Factors for Hypertension. Int J Mol Sci 2018;19:1724.

31. Wu J, Xun P, Tang Q, et al. Circulating magnesium levels and incidence of coronary heart diseases, hypertension, and type 2 diabetes mellitus: a meta-analysis of prospective cohort studies. Nutr J 2017;16:60.

32. Han H, Fang X, Wei X, et al. Dose-response relationship between dietary magnesium intake, serum magnesium concentration and risk of hypertension: a systematic review and meta-analysis of prospective cohort studies. Nutr J 2017;16:26.

33. Zhang X, Li Y, Del Gobbo LC, et al. Effects of Magnesium Supplementation on Blood Pressure: A Meta-Analysis of Randomized Double-Blind Placebo-Controlled Trials. Hypertension 2016;68:324–33.

34. Dibaba D, Xun P, Song Y, et al. The effect of magnesium supplementation on blood pressure in individuals with insulin resistance, prediabetes, or noncommunicable chronic diseases: a meta-analysis of randomized controlled trials. Am J Clin Nutr 2017;106:921–9.

35. Rosanoff A, Plesset MR. Oral magnesium supplements decrease high blood pressure (SBP>155 mmHg) in hypertensive subjects on anti-hypertensive medications: a targeted meta-analysis.Magnes Res. 2013;26:93–9.

36. Jiki Z, Lecour S,Nduhirabandi F. Cardiovascular Benefits of Dietary Melatonin: A Myth or a Reality? Front Physiol 2018;9:528.

37. Pechanova O, Paulis L, Simko F. Peripheral and central effects of melatonin on blood pressure regulation.Int J Mol Sci 2014;15:17920–37.

38. Baker J, Kimpinski K. Role of melatonin in blood pressure regulation: An adjunct anti-hypertensive agent. Clin Exp Pharmacol Physiol 2018;45:755–66.

39. Hadi A, Ghaedi E, Moradi S, et al. Effects of Melatonin Supplementation On Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Horm Metab Res 2019;51:157–64.

40. Możdżan M, Możdżan M, Chałubiński M, et al. The effect of melatonin on circadian blood pressure in patients with type 2 diabetes and essential hypertension. Arch Med Sci 2014;10:669–75.

41. Grossman E, Laudon M, Zisapel N. Effect of melatonin on nocturnal blood pressure: meta-analysis of randomized controlled trials. Vasc Health Risk Manag 2011;7:577–84.

42. Rahbari-Oskoui FF, Abramson JL, Bruckman AM, et al. Nighttime administration of high-dose, sustained-release melatonin does not decrease nocturnal blood pressure in African-American patients: Results from a preliminary randomized, crossover trial. Complement Ther Med 2019;43:157–64.

43. Belcaro G, Cornelli U, Luzzi R, et al. Pycnogenol® supplementation improves health risk factors in subjects with metabolic syndrome. Phytother Res 2013;27:1572–8.

44. Hu S, Belcaro G, Cornelli U, et al. Effects of Pycnogenol® on endothelial dysfunction in borderline hypertensive, hyperlipidemic, and hyperglycemic individuals: the borderline study. Int Angiol 2015;34:43–52.

45. Pourmasoumi M, Hadi A, Mohammadi H, et al. Effect of pycnogenol supplementation on blood pressure: A systematic review and meta-analysis of clinical trials. Phytother Res 2020;34:67–76.

46. Zhang Z, Tong X, Wei YL, et al. Effect of Pycnogenol Supplementation on Blood Pressure: A Systematic Review and Meta-analysis. Iran J Public Health 2018;47:779–87.

47. Fogacci F, Tocci G, Sahebkar A, et al. Effect of Pycnogenol on Blood Pressure: Findings From a PRISMA Compliant Systematic Review and Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled, Clinical Studies. Angiology 2020;71:217–25.

48. Washburn S, Burke GL, Morgan T, Anthony M. Effect of soy protein supplementation on serum lipoproteins, blood pressure, and menopausal symptoms in perimenopausal women. Menopause1999;6:7-13.

49. Rivas M, Garay RP, Escanero JF, et al. Soy milk lowers blood pressure in men and women with mild to moderate essential hypertension. J Nutr 2002;132:1900-2.

50. Burke V, Hodgson JM, Beilin LJ, et al. Dietary protein and soluble fiber reduce ambulatory blood pressure in treated hypertensives. Hypertension2001;38:821-6.

51. He J, Gu D, Wu X, et al. Effect of soybean protein on blood pressure: a randomized, controlled trial. Ann Intern Med 2005;143:1-9.

52. Welty FK, Lee KS, Lew NS, Zhou JR. Effect of soy nuts on blood pressure and lipid levels in hypertensive, prehypertensive, and normotensive postmenopausal women. Arch Intern Med 2007;167:1060-7.

53. Bkaily G, Jazzar A, Normand A, et al. Taurine and cardiac disease: state of the art and perspectives. Can J Physiol Pharmacol 2020;98:67–73.

54. Guizoni DM, Vettorazzi JF, Carneiro EM, et al. Modulation of endothelium-derived nitric oxide production and activity by taurine and taurine-conjugated bile acids. Nitric Oxide 2020;94:48–53.

55. Sun Q, Wang B, Li Y, et al. Taurine Supplementation Lowers Blood Pressure and Improves Vascular Function in Prehypertension: Randomized, Double-Blind, Placebo-Controlled Study. Hypertension 2016;67:541–9.

56. Waldron M, Patterson SD, Tallent J, et al. The Effects of Oral Taurine on Resting Blood Pressure in Humans: a Meta-Analysis.Curr Hypertens Rep 2018;20:81.

57. Morelli MB, Gambardella J, Castellanos V, et al. Vitamin C and Cardiovascular Disease: An Update. Antioxidants 2020;9:1227.

58. Ran L, Zhao W, Tan X, et al. Association between Serum Vitamin C and the Blood Pressure: A Systematic Review and Meta-Analysis of Observational Studies. Cardiovasc Ther 2020;2020:4940673.

59. Myint PK, Luben RN, Wareham NJ, et al. Association between plasma vitamin C concentrations and blood pressure in the European prospective investigation into cancer-Norfolk population-based study. Hypertension 2011;58:372–9.

60. Guan Y, Dai P, Wang H. Effects of vitamin C supplementation on essential hypertension: A systematic review and meta-analysis. Medicine 2020;99:e19274.

61. Gambardella J, Khondkar W, Morelli MB, et al. Arginine and Endothelial Function. Biomedicines. 2020;8:277.

62. Khalaf D, Krüger M, Wehland M, et al. The Effects of Oral l-Arginine and l-Citrulline Supplementation on Blood Pressure. Nutrients 2019;11:1679.

63. Higashi Y, Oshima T, Watanabe M, et al. Renal response to L-arginine in salt-sensitive patients with essential hypertension. Hypertension 1996r;27:643–8.

64. Campese VM, Amar M, Anjali C, et al. Effect of L-arginine on systemic and renal haemodynamics in salt-sensitive patients with essential hypertension. J Hum Hypertens 1997;11:527–32.

65. Martelli A, Testai L, Colletti A, et al. Coenzyme Q10: Clinical Applications in Cardiovascular Diseases. Antioxidants (Basel) 2020;9:341.

66. Ho MJ, Li EC, Wright JM. Blood pressure lowering efficacy of coenzyme Q10 for primary hypertension. Cochrane Database Syst Rev 2016;3:CD007435.

67. Tabrizi R, Akbari M, Sharifi N, et al. The Effects of Coenzyme Q10 Supplementation on Blood Pressures Among Patients with Metabolic Diseases: A Systematic Review and Meta-analysis of Randomized Controlled Trials. High Blood Press Cardiovasc Prev 2018;25:41–50.

68. Walker AF, Marakis G, Morris AP, et al. Promising hypotensive effect of hawthorn extract: a randomized double-blind pilot study of mild, essential hypertension. Phytotherapy Res 2002;16:48–54.

69. Asgary S, Naderi GH, Sadeghi M, et al. Antihypertensive effect of Iranian Crataegus curvisepala Lind.: a randomized, double-blind study. Drugs Exp Clin Res 2004;30:221–5.

70. Walker AF, Marakis G, Simpson E, et al. Hypotensive effects of hawthorn for patients with diabetes taking prescription drugs: a randomised controlled trial. Br J Gen Pract 2006;56:437–43.

71. Wang J, Xiong X, Feng B. Effect of crataegus usage in cardiovascular disease prevention: an evidence-based approach. Evid Based Complement Alternat Med 2013;2013:149363.

72. Asgary S, Keshvari M. Effects of Citrus sinensis juice on blood pressure. ARYA atheroscler 2013;9:98–101.

73. Morand C, Dubray C, Milenkovic D, et al. Hesperidin contributes to the vascular protective effects of orange juice: a randomized crossover study in healthy volunteers. Am J Clin Nutr 2011;93:73–80.

74. Valls RM, Pedret A, Calderón-Pérez L, et al. Effects of hesperidin in orange juice on blood and pulse pressures in mildly hypertensive individuals: a randomized controlled trial (Citrus study). Eur J Nutr 2021;60:1277–88.

75. Milenkovic D, Deval C, Dubray C, et al. Hesperidin displays relevant role in the nutrigenomic effect of orange juice on blood leukocytes in human volunteers: a randomized controlled cross-over study. PloS one 2011;6:e26669.

76. Homayouni F, Haidari F, Hedayati M, et al. Blood pressure lowering and anti-inflammatory effects of hesperidin in type 2 diabetes; a randomized double-blind controlled clinical trial. Phytotherapy Res 2018;32:1073–9.

77. Alhabeeb H, Sohouli MH, Lari A, et al. Impact of orange juice consumption on cardiovascular disease risk factors: a systematic review and meta-analysis of randomized-controlled trials. Crit Rev Food Sci Nutr 2020:1–14.

78. Mohammadi M, Ramezani-Jolfaie N, Lorzadeh E, et al. Hesperidin, a major flavonoid in orange juice, might not affect lipid profile and blood pressure: A systematic review and meta-analysis of randomized controlled clinical trials. Phytother Res 2019 Mar;33:534–45.

79. Mas-Capdevila A, Teichenne J, Domenech-Coca C, et al. Effect of Hesperidin on Cardiovascular Disease Risk Factors: The Role of Intestinal Microbiota on Hesperidin Bioavailability. Nutrients. 2020;12:1488.

80. Romani A, Ieri F, Urciuoli S, et al. Health Effects of Phenolic Compounds Found in Extra-Virgin Olive Oil, By-Products, and Leaf of Olea europaea L. Nutrients 2019;11:1776.

81. Hermans MP, Lempereur P, Salembier JP, et al. Supplementation Effect of a Combination of Olive (Olea europea L.) Leaf and Fruit Extracts in the Clinical Management of Hypertension and Metabolic Syndrome. Antioxidants (Basel) 2020;9:872.

82. Lockyer S, Rowland I, Spencer JPE, et al. Impact of phenolic-rich olive leaf extract on blood pressure, plasma lipids and inflammatory markers: a randomised controlled trial. Eur J Nutr 2017;56:1421–32.

83. Susalit E, Agus N, Effendi I, et al. Olive (Olea europaea) leaf extract effective in patients with stage-1 hypertension: comparison with Captopril. Phytomedicine 2011;18:251–8.

84. de la Guía-Galipienso F, Martínez-Ferran M, Vallecillo N, et al. Vitamin D and cardiovascular health. Clin Nutr 2021;40:2946–57.

85. Lin L, Zhang L, Li C, et al. Vitamin D and Vitamin D Receptor: New Insights in the Treatment of Hypertension. Curr Protein Pept 2019;20:984–95.

86. Zhang D, Cheng C, Wang Y, et al. Effect of Vitamin D on Blood Pressure and Hypertension in the General Population: An Update Meta-Analysis of Cohort Studies and Randomized Controlled Trials. Prev Chronic Dis 2020;17:E03.

87. Legarth C, Grimm D, Wehland M, et al. The Impact of Vitamin D in the Treatment of Essential Hypertension. Int J Mol Sci 2018;19:455.

88. He S, Hao X. The effect of vitamin D3 on blood pressure in people with vitamin D deficiency: A system review and meta-analysis. Medicine (Baltimore) 2019;98:e15284.

89. Zhu YB, Li ZQ, Ding N, et al. The association between vitamin D receptor gene polymorphism and susceptibility to hypertension: a meta-analysis. Eur Rev Med Pharmacol Sci 2019;23:9066–74.

90. Llopis-González A, Rubio-López N, Pineda-Alonso M, et al. Hypertension and the fat-soluble vitamins A, D and E. Int J Environ Res Public Health 2015;12:2793–809.

91. Kuwabara A, Nakade M, Tamai H, et al. The association between vitamin E intake and hypertension: results from the re-analysis of the National Health and Nutrition Survey. J Nutr Sci Vitaminol (Tokyo) 2014;60:239–45.

92. Ziegler M, Wallert M, Lorkowski S, et al. Cardiovascular and Metabolic Protection by Vitamin E: A Matter of Treatment Strategy? Antioxidants (Basel) 2020;9:935.

93. Emami MR, Safabakhsh M, Alizadeh S, et al. Effect of vitamin E supplementation on blood pressure: a systematic review and meta-analysis. J Hum Hypertens 2019;33:499–507.

94. Ramanathan N, Tan E, Loh LJ, et al. Tocotrienol is a cardioprotective agent against ageing-associated cardiovascular disease and its associated morbidities. Nutr Metab (Lond) 2018;15:6.

95. Asgary S, Naderi GH, Sarrafzadegan N, et al. Antihypertensive and antihyperlipidemic effects of Achillea wilhelmsii. Drugs Exp Clin Res 2000;26:89–93.

96. Khan AU, Gilani AH. Blood pressure lowering, cardiovascular inhibitory and bronchodilatory actions of Achillea millefolium. Phytothe Res 2011;25:577–83.

97. Arias-Durán L, Estrada-Soto S, Hernández-Morales M, et al. Antihypertensive and vasorelaxant effect of leucodin and achillin isolated from Achillea millefolium through calcium channel blockade and NO production: In vivo, functional ex vivo and in silico studies. J Ethnopharmacol 2021;273:113948.

98. de Souza P, Gasparotto A, Crestani S, et al. Hypotensive mechanism of the extracts and artemetin isolated from Achillea millefolium L. (Asteraceae) in rats. Phytomedicine 2011;18:819–25.

99. Niazmand S, Harandizadeh F, Mahmoudabady M, et al. Mechanism of vasorelaxation induced by Achillea wilhelmsii in rat isolated thoracic aorta. Adv Biomed Res 2014;3:91.

100. Sun X, Li H, He X, et al. The association between calcium supplement and preeclampsia and gestational hypertension: a systematic review and meta-analysis of randomized trials. Hypertens Pregnancy 2019;38:129–39.

101. Cormick G, Belizán JM. Calcium Intake and Health. Nutrients 2019;11:1606.

102. Cormick G, Ciapponi A, Cafferata ML, et al. Calcium supplementation for prevention of primary hypertension. Cochrane Database Syst Rev 2015;6:Cd010037.

103. van Mierlo LA, Arends LR, Streppel MT, et al. Blood pressure response to calcium supplementation: a meta-analysis of randomized controlled trials. J Hum Hypertens 2006;20:571–80.

104. Hulbert M, Turner ME, Hopman WM, et al. Changes in vascular calcification and bone mineral density in calcium supplement users from the Canadian Multi-center Osteoporosis Study (CaMOS). Atherosclerosis 2020;296:83–90.

105. Khan SU, Khan MU, Riaz H, et al. Effects of Nutritional Supplements and Dietary Interventions on Cardiovascular Outcomes: An Umbrella Review and Evidence Map. Ann Intern Med 2019;171:190–8.

106. Myung SK, Kim HB, Lee YJ, et al. Calcium Supplements and Risk of Cardiovascular Disease: A Meta-Analysis of Clinical Trials. Nutrients 2021;13:368.

107. Morvaridzadeh M, Sepidarkish M, Fazelian S, et al. Effect of Calcium and Vitamin D Co-supplementation on Blood Pressure: A Systematic Review and Meta-Analysis. Clin Ther 2020;42:e45–e63.

108. Dubey MP, Srimal RC, Nityanand S, Dhawan BN. Pharmacological studies on coleonol, a hypotensive diterpene from Coleus forskohlii. J Ethnopharmacol 1981;3:1–13.

109. Lindner E, Dohadwalla AN, Bhattacharya BK. Positive inotropic and blood pressure lowering activity of a diterpene derivative isolated from Coleus forskohli: Forskolin. Arzneimittelforschung. 1978;28:284–9.

110. Jagtap M, Chandola HM, Ravishankar B. Clinical efficacy of Coleus forskohlii (Willd.) Briq. (Makandi) in hypertension of geriatric population. Ayu. 2011;32:59–65.

111. Baumann G, Felix S, Sattelberger U, Klein G. Cardiovascular effects of forskolin (HL 362) in patients with idiopathic congestive cardiomyopathy—a comparative study with dobutamine and sodium nitroprusside. J Cardiovasc Pharmacol 1990;16:93–100.

112. Zhang B, Liu J, Liu C, et al. Bifunctional peptides with antioxidant and angiotensin-converting enzyme inhibitory activity in vitro from egg white hydrolysates. J Food Biochem 2020 09;44:e13347.

113. Lee DE, Jung TH, Jo YN, et al. Enzymatic Hydrolysis of Egg White Protein Exerts a Hypotensive Effect in Spontaneously Hypertensive Rats. Food Sci Anim Resour 2019;39:980–7.

114. Plat J,Severins N, Morrison S, et al. Effects of NWT-03, an egg-protein hydrolysate, on blood pressure in normotensive, high-normotensive and mild-hypertensive men and women: a dose-finding study. Br J Nutr 2017;117:942–50.

115. Lucey AJ, Heneghan C, Manning E, et al. Effect of an egg ovalbumin-derived protein hydrolysate on blood pressure and cardiovascular risk in adults with a mildly elevated blood pressure: a randomized placebo-controlled crossover trial. Eur J Nutr 2019;58:2823–33.

116. Samsamikor M, Mackay D, Mollard RC, et al. A double-blind, randomized, crossover trial protocol of whole hemp seed protein and hemp seed protein hydrolysate consumption for hypertension. Trials 2020;21:354.

117. Malomo SA, Onuh JO, Girgih AT, et al. Structural and Antihypertensive Properties of Enzymatic Hemp Seed Protein Hydrolysates. Nutrients 2015;7:7616–32.

118. Girgih AT, Alashi AM, He R, et al. A novel hemp seed meal protein hydrolysate reduces oxidative stress factors in spontaneously hypertensive rats. Nutrients 2014;6:5652–66.

119. Girgih A, Alashi A, He R, et al. Preventive and treatment effects of a hemp seed (Cannabis sativa L.) meal protein hydrolysate against high blood pressure in spontaneously hypertensive rats. Eur J Nutr 2014;53:1237–46.

120. Lobay D. Rauwolfia in the Treatment of Hypertension. Integr Med (Encinitas) 2015;14:40–6.

121. Shamon SD,Perez MI. Blood pressure-lowering efficacy of reserpine for primary hypertension. Cochrane Database Syst Rev 2016;12:CD007655.

122. Ryan JJ, Hanes DA, Corroon J, et al. Prospective Safety Evaluation of a Cardiovascular Health Dietary Supplement in Adults with Prehypertension and Stage I Hypertension. J Altern Complement Med 2019;25:249–56.

123. Poggiogalle E, Fontana M, Giusti AM, et al. Amino Acids and Hypertension in Adults. Nutrients 2019;11:1459.

124. Feltkamp H, Meurer KA, Godehardt E. Tryptophan-induced lowering of blood pressure and changes of serotonin uptake by platelets in patients with essential hypertension. Klin Wochenschr 1984;62:1115–9.

125. Cade JR, Fregly MJ, Privette M. Effect of tryptophan and 5-hydroxytryptophan on the blood pressure of patients with mild to moderate hypertension. Amino Acids 1992;2:133–42.

126. Nazaruk J, Orlikowski P. Phytochemical profile and therapeutic potential of Viscum album L. Nat Prod Res 2016;30:373–85.

127. Khan T, Ali S, Qayyum R, et al. Intestinal and vascular smooth muscle relaxant effect of Viscum album explains its medicinal use in hyperactive gut disorders and hypertension. BMC Complement Altern Med 2016;16:251.

128. Poruthukaren KJ, Palatty PL, Baliga MS, et al. Clinical evaluation of Viscum album mother tincture as an antihypertensive: a pilot study. J Evid Based Complementary Altern Med 2014;19:31–5.

129. Bowman IA. The everlasting mistletoe and the cardiovascular system. Texas Heart Inst J 1990;17:310–4.

130. Teunissen-Beekman KF, Dopheide J,Geleijnse JM, et al. Dietary proteins improve endothelial function under fasting conditions but not in the postprandial state, with no effects on markers of low-grade inflammation. Br J Nutr 2015;114:1819–28.

131. Teunissen-Beekman KF, Dopheide J,Geleijnse JM, et al. Differential effects of proteins and carbohydrates on postprandial blood pressure-related responses. Br J Nutr 2014;112:600–8.

132. Dugardin C, Cudennec B, Tourret M, et al. Explorative Screening of Bioactivities Generated by Plant-Based Proteins after In Vitro Static Gastrointestinal Digestion. Nutrients 2020;12:3746.

133. Teunissen-Beekman K, Dopheide J, Geleijnse J, et al. Protein supplementation lowers blood pressure in overweight adults: effect of dietary proteins on blood pressure (PROPRES), a randomized trial. Am J Clin Nutr 2012;95:966–71.

134. Li H, PrairieN, Udenigwe C, et al. Blood pressure lowering effect of a pea protein hydrolysate in hypertensive rats and humans. J Agric Food Chem 2011;59:9854–60.

135. Tran HB, Yamamoto A, Matsumoto S, et al. Hypotensive effects and angiotensin-converting enzyme inhibitory peptides of reishi (Ganoderma lingzhi) auto-digested extract. Molecules 2014;19:13473–85.

136. Wu Q, Li Y, Peng K, et al. Isolation and Characterization of Three Antihypertension Peptides from the Mycelia of Ganoderma Lucidum (Agaricomycetes). J Agric Food Chem 2019;67:8149–59.

137. Chu TT, Benzie IF, Lam CW, et al. Study of potential cardioprotective effects of Ganoderma lucidum (Lingzhi): results of a controlled human intervention trial. Br J Nutr 2012;107:1017–27.

138. Klupp NL, Kiat H, Bensoussan A, et al. A double-blind, randomised, placebo-controlled trial of Ganoderma lucidum for the treatment of cardiovascular risk factors of metabolic syndrome. Sci Rep 2016;6:29540.

139. Jin H, Zhang G, Cao X, et al. Treatment of hypertension by ling zhi combined with hypotensor and its effects on arterial, arteriolar and capillary pressure and microcirculation. In: Nimmi H, Xiu RJ, Sawada T, Zheng C (eds). Microcirculatory Approach to Asian Traditional Medicine. New York: Elsevier Science, 1996, 131–8.

140. Olas B. Sea buckthorn as a source of important bioactive compounds in cardiovascular diseases. Food Chem Toxicol 201697:199–204.

141. Skalski B, Kontek B, Olas B, et al. Phenolic fraction and nonpolar fraction from sea buckthorn leaves and twigs: chemical profile and biological activity. Future Med Chem 2018;10:2381–94.

142. Zhou F, Zhang J, Zhao A, et al. Effects of sea buckthorn puree on risk factors of cardiovascular disease in hypercholesterolemia population: a double-blind, randomized, placebo-controlled trial. Anim Biotechnol 2020:1–9.

143. Vashishtha V, Barhwal K, Kumar A, et al. Effect of seabuckthorn seed oil in reducing cardiovascular risk factors: A longitudinal controlled trial on hypertensive subjects. Clin Nutr 2017;36:1231–8.

144. Markovitz JH, Matthews KA, Kannel WB, et al. Psychological predictors of hypertension in the Framingham Study. Is there tension in hypertension?JAMA 1993;270:2439-43.

145. Schnall PL, Schwartz JE, Landesbergis PA, et al. Relation between job strain, alcohol, and ambulatory blood pressure. Hypertension 1992;19:488-94.

146. Matthews KA, Cottington EM, Talbott E, et al. Stressful work conditions and diastolic blood pressure among blue collar factory workers. Am J Epidemiol 1987;126:280-91.

147. Pickering TG. Does psychological stress contribute to the development of hypertension and coronary heart disease? Eur J Clin Pharmacol 1990;39(Suppl 1):S1-S7.

148. Perini C, Müller FB, Bühler FR. Suppressed aggression accelerates early development of essential hypertension. J Hypertens 1991;9:499-503.

149. Eisenberg DM, Delbanco TL, Berkey CS, et al. Cognitive behavioral techniques for hypertension: are they effective? Ann Intern Med 1993;118:964-72.

150. Irvine MJ, Logan AG. Relaxation behavior therapy as sole treatment for mild hypertension. Psychosomatic Med 1991;53:587-97.

151. Johnston DW, Gold A, Kentish J, et al. Effect of stress management on blood pressure in mild primary hypertension. BMJ 1993;306:963-6.

152. Patel CH. Yoga and bio-feedback in the management of hypertension. Lancet 1973;2:1973-5.

153. Schneider RH, Staggers F, Alexander C, et al. A randomized controlled trial of stress reduction for hypertension in older African Americans. Hypertension 1995;26:820-9.

154. Patel C, Marmot MG, Terry DJ, et al. Trial of relaxation in reducing coronary risk: four year follow up. BMJ 1985;290:1103-6.

155. Lee HS, Kim JY. Effects of acupuncture on blood pressure and plasma renin activity in two-kidney one clip goldblatt hypertensive rats. Am J Chin Med 1994;22:215-9.

156. Chiu YJ, Chi A, Reid IA. Cardiovascular and endocrine effects of acupuncture in hypertensive patients. Clin Exper Hypertens 1997;19:1047-63.

157. Peng L, Feng-yen S, An-zhong Z. The effect of acupuncture on blood pressure: the interrelation of sympathetic activity and endogenous opioid peptides. Acupunct Electrother Res 1983;8:45-56.

158. Zhou Y, Wang Y, Fang Z, et al. Influence of acupuncture on blood pressure, contents of NE, DA and 5-HT of SHR and the interrelation between blood pressure and whole blood viscosity. Chen Tzu Yen Chiu 1995;20:55-61 [in Chinese].

159. Radzievsky SA, Lebedeva OD, Fisenko LA, Majskaja SA. Function of myocardial contraction and relaxation in essential hypertension in dynamics of acupuncture therapy. Am J Chin Med 1989;17:111-7.

160. Williams T, Mueller K, Cornwall MW. Effect of acupuncture-point stimulation on diastolic blood pressure in hypertensive subjects: a preliminary study. Phys Ther 1991;71:523-9.

161. Weihai Y, Hongxu L. Clinical observation on the immediate hypotensive effect of zanzhu point. J Tradit Chin Med 1996;16:273-4.

162. Utsunomiya N, Shigematsu Y, Ikeda K, et al. Fall in high blood pressure after applying acupuncture to SHR. Jpn Heart J 1978;19:594.

163. Yiping Z, Qiong C, Zhengming H, Yinong C. Experimental research on treatment of hypertension with acupuncture. J Tradit Chin Med 1993;13:277-80.

164. Tam K-C, Yiu H-H. The effect of acupuncture on essential hypertension. Am J Chin Med 1975;3:369-75.

165. Kraft K, Coulon S. Effect of a standardized acupuncture treatment on complains, blood pressure and serum lipids of hypertensive, postmenopausal women. A randomized, controlled clinical study. Forsch Komplementarmed 1999;6:74-9 [in German].

166. Rongxing Z, Yanhua Z, Lu Y. Hypotensive effect of ototherapy in relation to symptomatic and dispositional types of patients. J Tradit Chin Med 1992;12:124-8.

167. Kangmei C, Shulian Z, Ying Z. Clinical application of traditional auriculoacupoint therapy (continued). J Tradit Chin Med 1993;13:152-4.

168. Rongxing Z, Yanhua Z, Jialiang W, et al. Anti-hypertensive effect of auriculo-acupoint pressing therapy—clinical analysis of 274 cases. J Tradit Chin Med 1991;11:189-92.

169. Peng Y, Fenglan L, Xin W. Treatment of essential hypertension with auriculopressure. J Tradit Chin Med 1991;1117-21.

170. Tran T, Kirby J. Effects of upper cervical adjustments upon the normal physiology of the heart. ACA J Chiro 1977;XI:S58-62.

171. McGuiness J, Vicenzino B, Wright A. The influence of a cervical mobilization technique on respiratory and cardiovascular function. Man Ther 1997;2:216-20.

172. Vicenzino B, Cartwright T, Collins D. Cardiovascular and respiratory changes produced by lateral glide mobilization of the cervical spine Manual Therapy 1998;3(2):67-71.

173. Dulgar G, Hill D, Sirucek A, et al. Evidence for possible anti-hypertensive effect of basic technique apex contact adjusting. J Chiro 1980;14:S97-S102.

174. Nansel D, Jansen R, Cremata E, et al. Effects of cervical adjustments on lateral-flexion passive end-range asymmetry and on blood pressure, heart rate and plasma catecholamine levels. J Manipulative Physiol Ther 1991;14:450-6.

175. Fichera AP, Celander DR. Effect of osteopathic manipulative therapy on autonomic tone as evidenced by blood pressure change and activity of the fibrinolytic system. J Am Osteopath Assoc 1969;68:1036-8.

176. McKnight M, DeBoer KD. Preliminary study of blood pressure changes in normotensive patients under chiropractic care. J Manipulative Physiol Ther 1988;11:261-6.

177. Yates RG, Lamping DL, Nancy LA, Wright C. Effects of chiropractic treatment on blood pressure and anxiety: a randomized, controlled trial. J Manipulative Physiol Ther 1988;11:484-8.

178. Morgan JP, Dickey JL, Hunt HH, Hudgins PM. A controlled trial of spinal manipulation in the management of hypertension. J Am Osteopath Assoc 1985;85(5):308-12.

179. Mannino J. The application of neurologic reflexes to the treatment of hypertension. J Am Osteopath Assoc 1979;79:225-31.

180. Wagnon RJ, Sandefur RM, Ratliff CR. Serum aldosterone changes after specific chiropractic manipulation. Am J Chiropr Med 1988;1(2):66-70.

181. Goodman R. Hypertension and the atlas subluxation complex. Chiropractic: J Chiropractic Res Clin Invest 1992;8(2)30-2.

182. Rossner S, Andersson IL, Ryttig K. Effects of a dietary fibre supplement to a weight reduction programme on blood pressure. A randomized, double-blind, placebo-controlled study. Acta Med Scand 1988;223:353-7.

183. Eliasson K, Ryttig KR, Hylander B, Rossner S. A dietary fibre supplement in the treatment of mild hypertension. A randomized, double-blind, placebo-controlled trial. J Hypertens 1992;10:195-9.

184. Schlamowitz P, Halberg T, Warnoe O, et al. Treatment of mild to moderate hypertension with dietary fibre. Lancet 1987;2:622-3.

185. Fehily AM, Burr ML, Butland BK, Eastham RD. A randomised controlled trial to investigate the effect of a high fibre diet on blood pressure and plasma fibrinogen. J Epidemiol Community Health 1986;40:334-7.

186. Swain JF, Rouse IL, Curley CB, Sacks FM. Comparison of the effects of oat bran and low-fiber wheat on serum lipoprotein levels and blood pressure. N Engl J Med 1990;322:147-52.

187. Rachima-Maoz C, Peleg E, Rosenthal T. The effect of caffeine on ambulatory blood pressure in hypertensive patients. Am J Hypertens 1998;11:1426-32.

188. Hodgoson JM, Buddey IB, Burke V, et al. Effects on blood pressure of drinking green and black tea. J Hypertens 1999;17:457-63.

189. Jee SH, He J, Whelton PK, et al. The effect of chronic coffee drinking on blood pressure. A meta-analysis of controlled clinical trials. Hypertension 1999;33:647-52.

190. Wakabayashi K, Kono S, Shinchi K, et al. Habitual coffee consumption and blood pressure: a study of self-defense officials in Japan. Eur J Epidemiol 1998;14:669-73.

191. Soriguer F, Rojo-Martinez G, Dobarganes MC, et al. Hypertension is related to the degradation of dietary frying oils. Am J Clin Nutr 2003;78:1092-7.

192. Page LB, Damon A, Moellering RC Jr. Antecedents of cardiovascular disease in six Solomon Islands Societies. Circulation 1974;44:1132-46.

193. Stamler J, Rose G, Elliott P, et al. Findings of the international cooperative INTERSALT study. Hypertension 1991;17(1 Suppl):I9-15.

194. MacGregor GA, Markandu ND, Sagnella GA, et al. Double-blind study of three sodium intakes and long-term effects of sodium restriction in essential hypertension. Lancet 1989;2:1244-7.

195. Cutler JA, Follmann D, Allender PS. Randomized trials of sodium reduction: an overview. Am J Clin Nutr 1997;65(Suppl):643S-51S.

196. Egan BM, Stepniakowski KT. Adverse effects of short-term, very-low-salt diets in subjects with risk-factor clustering. Am J Clin Nutr 1997;65(Suppl):671S-7S.

197. Engelhard YN, Gazer B, Paran E. Natural antioxidants from tomato extract reduce blood pressure in patients with grade-1 hypertension: a double-blind, placebo-controlled pilot study. Am Heart J 2006;151:100.

198. Margetts BM, Beilin LJ, Vandongen R, Armstrong BK. Vegetarian diet in mild hypertension: a randomised controlled trial. BMJ 1986;293:1468-71.

199. Cappuccio FP, MacGregor GA. Does potassium supplementation lower blood pressure? A meta-analysis of published trials. J Hypertens 1991;9:465-73.

200. Appel LJ, Moore TJ, Boarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med 1997;336:1117-24.

201. Svetkey LP, Simons-Morton D, Vollmer WM, et al. Effects of dietary patterns on blood pressure: a subgroup analysis of the Dietary Approaches to Stop Hypertension (DASH) randomized clinical trial. Arch Intern Med 1999;159:285-93.

202. Sachs FM, Svetkey LP, Vollmer WM, et al. Effects on Blood Pressure of Reduced Dietary Sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med 2001;344:3-10.

203. Zein M, Areas JL, Breuss GH. Effects of excess sucrose ingestion on the lifespan of SHR. J Am Coll Nutr 1989;8:435 [abstract #42].

204. Rebello T, Hodges RE, Smith JL. Short-term effects of various sugars on antinatriuresis and blood pressure changes in normotensive young men. Am J Clin Nutr 1983;38(1):84-94.

205. Preuss HG, Fournier RD. Effects of sucrose ingestion on blood pressure. Life Sci 1982;30:879-86.

206. Grant EC. Food allergies and migraine. Lancet 1979;i:966-9.

207. Narkiewicz K, Maraglino G, Biasion T, et al. Interactive effect of cigarettes and coffee on daytime systolic blood pressure in patients with mild essential hypertension. J Hypertens 1995;13:965-70.

208. Keil U, Liese A, Filipiak B, et al. Alcohol, blood pressure and hypertension. Novartis Round Symp 1998;216:125-44 [review].

209. Kukkonen K, Rauramaa R, Voutilainene E, Lansimies E. Physical training of middle-aged men with borderline hypertension. Ann Clin Res 1982;14(Suppl 34):139-45.

210. Young DR, Appel LG, Jee SH, Miller ER III. The effect of aerobic exercise and T'ai Chi on blood pressure in older people: results of a randomized trial. J Am Geriatr Soc 1999;47:277-84.

211. Kelley GA, Kelley KS. Progressive resistance exercise and resting blood pressure. A meta-analysis of randomized controlled trials. Hypertension 2000;35:838-43.

212. Alderman MH. Nonpharmacologic approaches to the treatment of hypertension. Lancet 1994;334:307-11 [review].

213. Stevens VJ, Obarzanek E, Cook NR, et al. Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, Phase II. Ann Intern Med 2001;134:1-11.

214. He J, Whelton PK, Appel LJ, et al. Long-term effects of weight loss and dietary sodium reduction on incidence of hypertension. Hypertension 2000;35:544-9.

215. G Bakris, M Dickholtz, P M Meyer, et al. Journal of Human Hypertension 21, 347-52; doi:10.1038/sj.jhh.1002133

Copyright © 2021 TraceGains, Inc. All rights reserved.

Learn more about TraceGains, the company.

The information presented by TraceGains is for informational purposes only. It is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. Self-treatment is not recommended for life-threatening conditions that require medical treatment under a doctor's care. For many of the conditions discussed, treatment with prescription or over the counter medication is also available. Consult your doctor, practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications. Information expires December 2021.

Copyright © 2021 TraceGains, Inc. Todos derechos reservados.

La información que se presenta en TraceGains no pretende nada más que informarle al consumidor con resultados interpretados de estudios científicos. A pesar de basarse en la investigación científica (humana, animal, o in vitro), en la experiencia clínica o en la observación de su aplicación en el uso tradicional, la información que se presenta en TraceGains y que se cita en cada artículo no pretende nada más que informarle al público. Además, es posible que no se logren los resultados presentados en todos los individuos. Enfermedades con peligro para la vida requieren tratamiento por prescripción facultativa y no se recomienda que intente curarlas sin que vigile un médico. Con respecto a muchas de las enfermedades discutidas, están disponibles medicamentos con y sin receta médica. Consúltese con su médico y/o farmacéutico para discutir cualquier problema de salud y siempre antes de utilizar cualquier suplemento o efectuar cualquier cambio con respecto a los medicamentos recetados que se toma. Esta información es válida hasta finales de Diciembre del 2021.